Get the Stockscreener App
23.35
1.57%
0.36
After Hours:
23.35
Amphastar Pharmaceuticals Inc stock is traded at $23.35, with a volume of 735.04K.
It is up +1.57% in the last 24 hours and down -15.67% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$22.99
Open:
$23.08
24h Volume:
735.04K
Relative Volume:
1.21
Market Cap:
$1.16B
Revenue:
$723.55M
Net Income/Loss:
$157.72M
P/E Ratio:
7.7833
EPS:
3
Net Cash Flow:
$170.15M
1W Performance:
-0.72%
1M Performance:
-15.67%
6M Performance:
-53.03%
1Y Performance:
-41.70%
1-Day Range:
$23.08
$23.61
1-Week Range:
$22.64
$24.92
52-Week Range:
$22.64
$53.95
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
23.35 | 1.16B | 723.55M | 157.72M | 170.15M | 3.00 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
JPMorgan Chase & Co. Sells 385,349 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Renaissance Technologies LLC Acquires 36,100 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 1-Year LowShould You Sell? - MarketBeat
LSV Asset Management Sells 44,000 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar stock hits 52-week low at $22.73 amid market challenges By Investing.com - Investing.com South Africa
Bessemer Group Inc. Buys 11,609 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar stock hits 52-week low at $22.73 amid market challenges - Investing.com Australia
Portolan Capital Management LLC Has $4.87 Million Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth? - Yahoo Finance
2 Reasons to Like AMPH and 1 to Stay Skeptical - Yahoo Finance
Amphastar Pharmaceuticals' (AMPH) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Hyaluronidase Market Growth, Trends & Insights 2024-2031 | Top - openPR.com
Federated Hermes Inc. Lowers Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Renaissance Group LLC Has $3.70 Million Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 12-Month LowShould You Sell? - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Amphastar Pharmaceuticals (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - Yahoo Finance
Dynamic Technology Lab Private Ltd Acquires 14,468 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Glucagon Market Set to Witness Significant Growth by 2032 | Eli - openPR.com
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock Position Increased by Vanguard Group Inc. - Defense World
Trexquant Investment LP Buys 16,248 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar at Needham Conference: Strategic Growth Amidst Challenges By Investing.com - Investing.com Canada
Amphastar stock hits 52-week low at $25.72 amid market challenges - Investing.com Australia
Amphastar stock hits 52-week low at $25.72 amid market challenges By Investing.com - Investing.com South Africa
Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 500 Shares of Stock - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading Down 3.1%Should You Sell? - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by American Century Companies Inc. - MarketBeat
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9th, 2021 - ACCESS Newswire
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt - simplywall.st
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023 - ACCESS Newswire
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - ACCESS Newswire
Amphastar Leadership Team Set for Major Investor Presentation at Needham Conference - Stock Titan
Amphastar Pharmaceuticals director sells $14,190 in stock - Investing.com India
Amphastar Pharmaceuticals director sells $14,190 in stock By Investing.com - Investing.com South Africa
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 10th, 2022 - ACCESS Newswire
92,904 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by Raymond James Financial Inc. - MarketBeat
Quantbot Technologies LP Invests $945,000 in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
(AMPH) Investment Report - news.stocktradersdaily.com
Fox Run Management L.L.C. Takes $688,000 Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):